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OBJECTIVE — To describe the diagnosis of a patient with neonatal diabetes who had been
misdiagnosed with type 1 diabetes and referred to our hospital for pancreas and kidney trans-
plantation because of end-stage renal disease.
RESEARCH DESIGN AND METHODS — A diagnosis of neonatal diabetes was made
after a molecular genetic study revealed a mutation in exon 34 of the ABCC8 gene. Pancreas
transplantation was ill-advised.
RESULTS — The patient was switched from insulin to glibenclamide 4 months after kidney
transplantation, conﬁrming that pancreas transplantation would not have been a good decision.
CONCLUSIONS — Thisistheﬁrstreportofapatientwithneonataldiabeteswhodeveloped
diabetic nephropathy that progressed to end-stage renal disease. This report illustrates that
careful endocrinological evaluation, including molecular genetic studies, if necessary, is man-
datory before a decision to perform a pancreas transplant is made.
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T
ype 1 diabetes is the main indicator
for simultaneous pancreas and kid-
ney transplantation (PKTx) in pa-
tients with end-stage renal disease
(ESRD). However, from a practical point
of view, it is important to consider that
patients with diabetes diagnosed at a
youngageandreceivinginsulintreatment
at the time of the evaluation for PKTx are
oftenassumedtohavetype1diabetes(1).
This may lead to unnecessary pancreas
transplantation in patients who, without
the presence of renal failure, have the ca-
pacity to secrete insulin with alternative
treatments.
Neonatal diabetes is a very rare con-
ditiondiagnosedwithintheﬁrst6months
oflifeandmaybepermanentortransient.
In transient neonatal diabetes, the disease
remits, although the patient may fre-
quently relapse (2,3). Neonatal diabetes
maybeaconsequenceofamutationinthe
ATP-sensitive K
 channel (KATP chan-
nel), and 90% of patients with neonatal
diabetes can transfer from insulin to sul-
fonylurea tablets, achieving good control.
Patients with neonatal diabetes can de-
velop diabetes complications, but to date
no neonatal diabetic patient with ESRD
has been reported.
We report a patient diagnosed with
type 1 diabetes and referred to our hospi-
tal for PKTx because of ESRD. After a ge-
netic diagnosis of neonatal diabetes, we
advised against pancreas transplantation
and recommended kidney transplanta-
tionalone,withtheaimoftransferringthe
patient from insulin to sulfonylurea ther-
apy posttransplant. This case report dem-
onstrates that young people can present
forms of insulin-treated diabetes other
than type 1 diabetes. Careful endocrino-
logical evaluation and molecular genetic
studies are determinant in the evaluation
of these patients.
RESEARCH DESIGN AND
METHODS— We report a 28-year-
old man, without a family history of dia-
betes,whowasdiagnosedwithdiabetesat
3 months of age and treated with insulin
untilhewas1yearold.At13yearsofage,
hyperglycemia relapsed with overt insuli-
nopenicsymptoms,andinsulintreatment
was reinitiated. He subsequently suffered
from brittle diabetes with frequent severe
hypoglycemic episodes and mean A1C
levels of 10%. He developed proliferative
retinopathy, severe autonomic neuropa-
thy with symptomatic gastroparesis, and
diabetic nephropathy that progressed to
requiring hemodialysis 11 months before
the transplant evaluation. His develop-
ment was normal, and neurological in-
volvement was absent.
On referral to our institution for PKTx,
GAD antibodies were negative, free C-
peptide concentration was 1.8 ng/ml, A1C
was 8.9%, and plasma creatinine was 6.4
mg/dl. He was not obese (weight 60 kg,
height 167 cm, and BMI 21.5 kg/m
2), and
insulin requirements were 25 units/day
(0.41 units   kg
1   day
1). Suspicion of
neonatal diabetes led to direct sequencing
of the KCNJ11 genes (K
 inwardly rectify-
ing channel, subfamily J, member 11 gene)
andABCC8(ATP-bindingcassette,subfam-
ily C, member 8 gene). KCNJ11 showed a
normal Kir6.2 sequence but with a substi-
tution of arginine by histidine in residue
1379inexon34oftheABCC8gene,encod-
ing the sulfonurea receptor (SUR)1 KATP
channelsubunit.Withthediagnosisofneo-
nataldiabetes,pancreastransplantationwas
not recommended and renal transplanta-
tion alone was proposed.
RESULTS— Renal transplantation was
performed with a kidney from a cadaveric
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tial bolus of antithymocyte globulin fol-
lowedbyprophylacticimmunosuppressive
therapy with prednisone, tacrolimus, and
mycophenolate mofetil. Prednisone was
discontinued 4 months after transplant, as
the patient was maintaining normal renal
function (1.4 mg/dl). At this time, insulin
requirements were 30 units/day (0.51
units   kg
1   day
1),A1Cwas11.1%,and
free C-peptide was 0.3 ng/ml. Transfer
from insulin to sulfonylurea therapy was
initiated with 30 mg/day glibenclamide,
and insulin was withdrawn 1 month
thereafter. Two months later, he was on
glibenclamide at 0.84 mg   kg
1   day
1.
Glycemic control improved, and no hy-
poglycemic episodes were reported. A1C
was 8%, and C-peptide concentration
was 2.3 ng/ml. In Table 1, the pre- and
posttransplant evolution of A1C, free C-
peptide, plasma creatinine level, and in-
sulin and glibenclamide doses are shown.
CONCLUSIONS — One-half of pa-
tients with neonatal diabetes are found to
have mutations in the KCNJ11 or ABCC8
genes,whichencodetheKir6.2andSUR1
subunits, respectively, of the KATP chan-
nel. Most patients with Kir6.2-mutation
neonatal diabetes have permanent diabe-
tes; however, in those with the SUR1 mu-
tation, neonatal diabetes is frequently
transitory. The KATP channel of pancre-
atic -cells regulates insulin release by
linking intracellular ATP production to
-cell membrane potential. On activating
KCNJ11 or ABCC8 mutations, the re-
sponse of the channel to ATP reduces,
thereby preventing channel closure and
consequent insulin secretion. Molecular
genetic diagnosis of neonatal diabetes has
a dramatic impact on diabetes therapy,
because sulfonylureas bind to SUR1 sub-
units of the KATP channel and close the
channel in an ATP-independent manner
(4).
Information regarding the appear-
ance of microangiopathic complications
in patients with neonatal diabetes is
scarce, being mainly related to retinopa-
thy (5). To our knowledge, no reports
have been published on a patient with
neonatal diabetes and diabetic nephropa-
thy in ESRD. However, over the years,
otherpatientswithneonataldiabeteshave
probably undergone pancreas transplan-
tation because they have not been appro-
priately diagnosed.
At present, PKTx is undoubtedly the
best therapeutic option for patients with
ESRD without contraindications. How-
ever, it cannot be forgotten that, com-
pared with kidney transplantation alone,
PKTx is associated with slightly greater
morbidity(6)andclearlyhighercosts.On
the other hand, the number of pancreata
available for transplantation is limited;
thus, we are obliged to rationalize their
usebyimplantationindonorrecipientsin
whom the expected beneﬁts are greater
than the possible inconveniences. In this
case, the dilemma was choosing either
PKTx,withthepossibilitythatthiswasan
unnecessary therapy, or carrying out iso-
lated kidney transplantation, risking a
possiblyunsuccessfultransfertosulfonyl-
urea therapy and losing the advantages of
double transplantation. This case illus-
trates that careful endocrinological evalu-
ation (including molecular genetic
studies, if necessary) of candidates for
PKTx is mandatory before a decision to
transplant is made.
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Table 1—Evolution of treatment of diabetes and metabolic control after kidney
transplantation
Pretransplant
4 months
posttransplant
5 months
posttransplant
6 months
posttransplant
A1C (%) 9.9 11.1 9.1 8
Basal free C-peptide (ng/ml) 1.8 0.3 2.0 2.3
Plasma creatinine (mg/dl) 8.9 1.4 1.2 1.3
Insulin dose (units/day) 25 30 30 to 0 0
Glibenclamide dose (mg/day) 0 0 30 to 45 45
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